AVANOS MEDICAL INC (AVNS) Fundamental Analysis & Valuation

NYSE:AVNS • US05350V1061

Current stock price

24.66 USD
+0.04 (+0.16%)
At close:
24.66 USD
0 (0%)
After Hours:

This AVNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. AVNS Profitability Analysis

1.1 Basic Checks

  • In the past year AVNS was profitable.
  • In the past year AVNS had a positive cash flow from operations.
  • In multiple years AVNS reported negative net income over the last 5 years.
  • AVNS had a positive operating cash flow in each of the past 5 years.
AVNS Yearly Net Income VS EBIT VS OCF VS FCFAVNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M -300M

1.2 Ratios

  • AVNS has a better Return On Assets (-6.79%) than 67.38% of its industry peers.
  • AVNS has a Return On Equity of -9.37%. This is in the better half of the industry: AVNS outperforms 68.98% of its industry peers.
  • AVNS's Return On Invested Capital of 1.47% is fine compared to the rest of the industry. AVNS outperforms 68.45% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AVNS is significantly below the industry average of 9.14%.
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROIC 1.47%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
AVNS Yearly ROA, ROE, ROICAVNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40

1.3 Margins

  • AVNS has a better Operating Margin (2.41%) than 67.38% of its industry peers.
  • In the last couple of years the Operating Margin of AVNS has declined.
  • The Gross Margin of AVNS (50.47%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of AVNS has remained more or less at the same level.
Industry RankSector Rank
OM 2.41%
PM (TTM) N/A
GM 50.47%
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
AVNS Yearly Profit, Operating, Gross MarginsAVNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AVNS Health Analysis

2.1 Basic Checks

  • AVNS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, AVNS has more shares outstanding
  • The number of shares outstanding for AVNS has been reduced compared to 5 years ago.
  • The debt/assets ratio for AVNS has been reduced compared to a year ago.
AVNS Yearly Shares OutstandingAVNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
AVNS Yearly Total Debt VS Total AssetsAVNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • AVNS has an Altman-Z score of 2.23. This is not the best score and indicates that AVNS is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.23, AVNS is doing good in the industry, outperforming 62.03% of the companies in the same industry.
  • The Debt to FCF ratio of AVNS is 2.33, which is a good value as it means it would take AVNS, 2.33 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.33, AVNS belongs to the top of the industry, outperforming 83.96% of the companies in the same industry.
  • A Debt/Equity ratio of 0.12 indicates that AVNS is not too dependend on debt financing.
  • AVNS has a Debt to Equity ratio of 0.12. This is in the better half of the industry: AVNS outperforms 64.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Altman-Z 2.23
ROIC/WACC0.17
WACC8.6%
AVNS Yearly LT Debt VS Equity VS FCFAVNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • AVNS has a Current Ratio of 2.15. This indicates that AVNS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of AVNS (2.15) is comparable to the rest of the industry.
  • AVNS has a Quick Ratio of 1.26. This is a normal value and indicates that AVNS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.26, AVNS is not doing good in the industry: 69.52% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.26
AVNS Yearly Current Assets VS Current LiabilitesAVNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AVNS Growth Analysis

3.1 Past

  • AVNS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.40%.
  • Measured over the past 5 years, AVNS shows a small growth in Earnings Per Share. The EPS has been growing by 3.80% on average per year.
  • Looking at the last year, AVNS shows a small growth in Revenue. The Revenue has grown by 1.95% in the last year.
  • The Revenue has been decreasing by -0.38% on average over the past years.
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%

3.2 Future

  • AVNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.51% yearly.
  • Based on estimates for the next years, AVNS will show a small growth in Revenue. The Revenue will grow by 3.19% on average per year.
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AVNS Yearly Revenue VS EstimatesAVNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
AVNS Yearly EPS VS EstimatesAVNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. AVNS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 26.23, the valuation of AVNS can be described as expensive.
  • 72.73% of the companies in the same industry are more expensive than AVNS, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.64, AVNS is valued at the same level.
  • A Price/Forward Earnings ratio of 24.15 indicates a rather expensive valuation of AVNS.
  • AVNS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AVNS is cheaper than 75.40% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of AVNS to the average of the S&P500 Index (21.36), we can say AVNS is valued inline with the index average.
Industry RankSector Rank
PE 26.23
Fwd PE 24.15
AVNS Price Earnings VS Forward Price EarningsAVNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AVNS indicates a somewhat cheap valuation: AVNS is cheaper than 73.80% of the companies listed in the same industry.
  • AVNS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AVNS is cheaper than 79.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 26.61
EV/EBITDA 20.71
AVNS Per share dataAVNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AVNS does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as AVNS's earnings are expected to grow with 16.51% in the coming years.
PEG (NY)3.04
PEG (5Y)6.9
EPS Next 2Y16.51%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVNS Dividend Analysis

5.1 Amount

  • No dividends for AVNS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVNS Fundamentals: All Metrics, Ratios and Statistics

AVANOS MEDICAL INC

NYSE:AVNS (5/1/2026, 8:10:37 PM)

After market: 24.66 0 (0%)

24.66

+0.04 (+0.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength16.77
Industry Growth32.3
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners97.14%
Inst Owner Change-0.16%
Ins Owners4.67%
Ins Owner Change5.19%
Market Cap1.15B
Revenue(TTM)701.20M
Net Income(TTM)-72.90M
Analysts43.33
Price TargetN/A
Short Float %4.51%
Short Ratio1.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.19%
Min EPS beat(2)14.64%
Max EPS beat(2)79.74%
EPS beat(4)4
Avg EPS beat(4)36.78%
Min EPS beat(4)11.11%
Max EPS beat(4)79.74%
EPS beat(8)5
Avg EPS beat(8)16.95%
EPS beat(12)7
Avg EPS beat(12)15.54%
EPS beat(16)10
Avg EPS beat(16)13.47%
Revenue beat(2)2
Avg Revenue beat(2)3.74%
Min Revenue beat(2)1.52%
Max Revenue beat(2)5.97%
Revenue beat(4)4
Avg Revenue beat(4)3.17%
Min Revenue beat(4)1.52%
Max Revenue beat(4)5.97%
Revenue beat(8)4
Avg Revenue beat(8)0.74%
Revenue beat(12)4
Avg Revenue beat(12)-0.83%
Revenue beat(16)4
Avg Revenue beat(16)-4.39%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-39.13%
EPS NY rev (1m)0%
EPS NY rev (3m)5.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 26.23
Fwd PE 24.15
P/S 1.64
P/FCF 26.61
P/OCF 15.35
P/B 1.47
P/tB 4.32
EV/EBITDA 20.71
EPS(TTM)0.94
EY3.81%
EPS(NY)1.02
Fwd EY4.14%
FCF(TTM)0.93
FCFY3.76%
OCF(TTM)1.61
OCFY6.51%
SpS15.08
BVpS16.73
TBVpS5.71
PEG (NY)3.04
PEG (5Y)6.9
Graham Number18.8117 (-23.72%)
Profitability
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROCE 1.86%
ROIC 1.47%
ROICexc 1.63%
ROICexgc 4.36%
OM 2.41%
PM (TTM) N/A
GM 50.47%
FCFM 6.15%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
ROICexc(3y)2.02%
ROICexc(5y)2.23%
ROICexgc(3y)5.81%
ROICexgc(5y)7.12%
ROCE(3y)2.3%
ROCE(5y)2.56%
ROICexgc growth 3Y-33.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-26.31%
ROICexc growth 5YN/A
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Debt/EBITDA 1.62
Cap/Depr 81.23%
Cap/Sales 4.51%
Interest Coverage 2.6
Cash Conversion 133.87%
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.26
Altman-Z 2.23
F-Score6
WACC8.6%
ROIC/WACC0.17
Cap/Depr(3y)52.99%
Cap/Depr(5y)50.85%
Cap/Sales(3y)3.25%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.19%
EBIT growth 3Y-39.42%
EBIT growth 5YN/A
EBIT Next Year165.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.01%
FCF growth 3Y-15.57%
FCF growth 5YN/A
OCF growth 1Y-25.82%
OCF growth 3Y-6.33%
OCF growth 5YN/A

AVANOS MEDICAL INC / AVNS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AVANOS MEDICAL INC?

ChartMill assigns a fundamental rating of 4 / 10 to AVNS.


What is the valuation status for AVNS stock?

ChartMill assigns a valuation rating of 4 / 10 to AVANOS MEDICAL INC (AVNS). This can be considered as Fairly Valued.


How profitable is AVANOS MEDICAL INC (AVNS) stock?

AVANOS MEDICAL INC (AVNS) has a profitability rating of 4 / 10.


What is the valuation of AVANOS MEDICAL INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for AVANOS MEDICAL INC (AVNS) is 26.23 and the Price/Book (PB) ratio is 1.47.


Can you provide the financial health for AVNS stock?

The financial health rating of AVANOS MEDICAL INC (AVNS) is 6 / 10.